Abstract
Rationale:Oxaliplatin is a key part of the standard treatment for colorectal cancer which is formally contraindicated in patients with severe renal dysfunction. Here, we investigated a safe and efficient dosing schedule of oxaliplatin in folinic acid, fluorouracil, and oxaliplatin (FOLFOX) regimen by monitoring total and free platinum concentrations in plasma.Patient concerns:A 47-year-old female with chronic hemodialysis was diagnosed with left-sided colon cancer and underwent colectomy. One year later, she was presented with omentum metastasis and needed further treatment.Diagnoses:The computed tomography (CT) scanning revealed multiple omental nodules. Positron emission tomography-CT (PET-CT) showed increased uptake of the nodules.Interventions:The patient was treated with FOLFOX therapy every 3 weeks. The oxaliplatin began with 50 mg/m2 and gradually increased 85 mg/m2 as in the standard regimen. A 4-hour dialysis was started 1 hour after the end of oxaliplatin infusion.Outcomes:The free platinum concentration time curve showed a biomodel pattern. The Cmax of the 1st peak we observed in our patients at the standard dose is comparable to patients with normal renal function. This patient was treated with FOLFOX for 12 courses. No apparent adverse effect was observed during the treatment.Lessons:The FOLFOX can be safely administered in hemodialysis patients on a long-term basis. Dose reduction of oxaliplatin is not necessarily needed if hemodialysis is performed soon after the infusion. Further studies are needed to distinguish between active and inactive oxaliplatin products during the 2nd peak of the free platinum concentration curve in this population.
Highlights
With the improvement of renal replacement therapy, the number of patients undergoing chronic hemodialysis has been increasing in recent years
We report the case of a hemodialysis patient with metastatic colon cancer who was safely treated with FOLFOX therapy by monitoring total and free platinum concentrations in plasma
The renal clearance of oxaliplatin is correlated with glomerular filtration rate and glomerular filtration is a primary mechanism of platinum clearance
Summary
With the improvement of renal replacement therapy, the number of patients undergoing chronic hemodialysis has been increasing in recent years. The patient provided written informed consent to the treatment and was willing to publish details of the medical record. Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy. Its elimination is delayed in patients with renal insufficiency and limited data are available on the pharmacokinetics, efficacy and safety of oxaliplatin in hemodialysis patients.[2] To date, only a few case reports of dosing oxaliplatin in hemodialysis patients have been published.[3,4,5,6,7] In this study, we report the case of a hemodialysis patient with metastatic colon cancer who was safely treated with FOLFOX therapy by monitoring total and free platinum concentrations in plasma
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
